Semaglutide in NYC: A Physician's Guide to GLP-1 Therapy for Weight Loss and Metabolic Health

Semaglutide — the active molecule behind Ozempic® and Wegovy® — has emerged as one of the most clinically significant advances in weight management and metabolic medicine in decades. At Regen Health Physicians NYC, Dr. Ajit Dhaliwal integrates GLP-1 receptor agonist therapy into a personalized regenerative medicine framework to help patients achieve sustainable metabolic health.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic analogue of the hormone GLP-1, which the gut naturally secretes after eating. GLP-1 receptors are found throughout the body, including the pancreas, brain, heart, and gut. When activated, they:

• Slow gastric emptying, promoting prolonged satiety after meals
• Stimulate glucose-dependent insulin secretion, improving blood sugar regulation
• Signal the hypothalamus to reduce appetite and food-seeking behavior
• Reduce glucagon release, limiting excess glucose production by the liver

At therapeutic doses, semaglutide produces clinically significant reductions in body weight, fasting glucose, HbA1c, and even cardiovascular risk markers.

Why Patients in NYC Are Seeking GLP-1 Therapy

The STEP clinical trials (Semaglutide Treatment Effect in People with Obesity) demonstrated average body weight reductions of 14.9% to 17.4% over 68 weeks — results that dwarf earlier pharmacological options. For patients who have struggled with traditional diet and exercise programs, semaglutide addresses the underlying neurobiological drivers of appetite dysregulation rather than relying solely on willpower.

NYC patients are coming to RHPNY's peptide therapy program for semaglutide because our approach integrates GLP-1 therapy within a broader metabolic and regenerative medicine context — not as a standalone prescription, but as part of a structured protocol that includes lab monitoring, nutritional guidance, and body composition optimization.

Who Is a Candidate?

Dr. Dhaliwal evaluates each patient carefully before initiating semaglutide. Ideal candidates generally include:

Adults With Excess Weight and Metabolic Comorbidities

Patients with a BMI ≥ 30, or ≥ 27 with weight-related conditions such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea may benefit significantly from GLP-1 therapy as part of a comprehensive chronic disease management plan.

Patients With Insulin Resistance or Pre-Diabetes

Even prior to a diabetes diagnosis, metabolic dysregulation — characterized by elevated fasting insulin, postprandial blood glucose spikes, and visceral adiposity — responds well to semaglutide. Early intervention can prevent progression to full type 2 diabetes.

Those Who Have Plateaued With Diet and Exercise

Obesity is a complex neuroendocrine disorder. Many patients who exercise regularly and eat well still struggle with weight due to hormonal adaptations. Semaglutide can reset the metabolic set point, making lifestyle interventions more effective.

How RHPNY Administers Semaglutide

Our protocol begins with a comprehensive metabolic panel, including fasting insulin, HbA1c, lipid fractions, thyroid function, and inflammatory markers. This data informs the starting dose and helps us monitor response over time.

Semaglutide is administered as a once-weekly subcutaneous injection. We typically begin at 0.25 mg weekly for four weeks, then titrate upward based on tolerance and clinical response. Most patients reach a maintenance dose of 1.0–2.4 mg per week depending on their individual goals and tolerance.

Patients are seen monthly for the first three months, then quarterly, with lab work at each visit to track metabolic markers, kidney function, and body composition.

Integrating GLP-1 With Regenerative Medicine

One of the distinguishing aspects of RHPNY's approach is that semaglutide is never prescribed in isolation. We pair GLP-1 therapy with:

• Hormone optimization: Low testosterone or thyroid dysfunction can undermine metabolic results. Our hormone optimization services address these concurrently.
• Anti-inflammatory protocols: Visceral fat drives systemic inflammation. As adiposity decreases, inflammatory markers typically follow — a process we support with targeted supplementation.
• Nutritional coaching: Appetite suppression creates a window of opportunity for building healthier habits. We work with patients to establish protein-rich, micronutrient-dense eating patterns that preserve lean muscle mass during weight loss.
• Body composition monitoring: We track fat mass versus lean mass, not just total weight, to ensure patients are losing fat rather than muscle.

Potential Side Effects and Safety Considerations

Semaglutide is generally well tolerated. The most common side effects are gastrointestinal — nausea, mild bloating, and reduced appetite — which typically resolve within the first 2–4 weeks as the dose is established.

Contraindications include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), as well as active pancreatitis. Dr. Dhaliwal reviews all relevant medical history before initiating therapy.

What Results Can NYC Patients Expect?

Most patients begin noticing reduced appetite within the first two weeks. Significant weight changes typically appear within 8–12 weeks of reaching the therapeutic dose. Over six months of consistent therapy combined with lifestyle support, patients commonly achieve:

• 10–20% total body weight reduction
• Improved fasting glucose and HbA1c
• Reduced blood pressure and triglyceride levels
• Improved energy and mood as metabolic health normalizes

Semaglutide is not a permanent solution on its own — it is most effective as part of a long-term lifestyle transformation strategy.

Taking the Next Step

If you are struggling with excess weight, metabolic syndrome, or pre-diabetes and are interested in a physician-supervised GLP-1 program in NYC, Regen Health Physicians offers a thorough evaluation and personalized protocol. Book a consultation with Dr. Dhaliwal to discuss whether semaglutide therapy is appropriate for your health goals.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Semaglutide and GLP-1 therapy are prescription treatments that require physician evaluation. Always consult a qualified healthcare provider before beginning any new treatment. Results vary by individual.